Quotient

JERSEY, Channel Islands, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced it has been named a winner in the prestigious 2021 BIG Innovation Awards presented by the Business Intelligence Group. The annual awards program recognizes the organizations, products and people that bring new ideas to life.

Quotient Limited Wins 2021 BIG Innovation Award

JERSEY, Channel Islands, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that on December 21, 2020, Ed Farrell delivered a notice of resignation from his position as the Company's Chief Operating Officer. Under Mr. Farrell's employment agreement, unless the Company elects otherwise, the resignation will take effect 12 months after the notice was given. Mr. Farrell stated that his resignation was due to personal reasons.

Quotient Limited Announces Departure of Chief Operating Officer

JERSEY, Channel Islands, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that it received a request from the U.S. Food and Drug Administration (FDA) for additional testing data regarding the 510(k) application for the Initial Serological Disease Screening Microarray (SDS) and MosaiQ instrument. The data the FDA has requested relates to specific individual performance characteristics of the assays on the microarray. In response to this request, the Company intends to re-submit its application, with the additional data requested by the FDA, in early 2021. Following that submission, the Company is targeting to receive the FDA 510(k) clearance in mid-2021.

Quotient Limited Provides Status Update on the Initial SDS Microarray and MosaiQ Instrument for the US Market

JERSEY, Channel Islands, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported preliminary EU field trial performance data for its MosaiQ Expanded Immunohematology (IH) Microarray. The data suggest that tests performed with Quotient's Microarray are highly accurate.

Quotient Limited Announces MosaiQ™ Expanded IH EU Field Trial Performance Data

Quotient Limited (QTNT) CEO Franz Walt on Q2 2021 Results - Earnings Call Transcript

JERSEY, Channel Islands, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today reported its second quarter fiscal 2021 results and summarized recent key developments.

Quotient Limited Reports Second Quarter Fiscal 2021 Results and Business Update

JERSEY, Channel Islands, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal second quarter ended September 30, 2020 will be released before market open on Monday, Nov 2, 2020.

Quotient Limited to Report Second Quarter 2021 Financial Results and Host Conference Call

JERSEY, Channel Islands, Sept.  28, 2020  (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), headquartered in Eysins, Switzerland, today announced that on September 25, 2020, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for Quotient's COVID-19 antibody test. The test detects antibodies generated in humans in response to the SARS-CoV-2 virus using Quotient's proprietary MosaiQ blood testing microarray technology. The antibody test was CE marked on May 1, 2020 and is now available in Europe and the US.

Quotient Limited Announces Receipt of U.S. FDA Emergency Use Authorization (EUA) for MosaiQ COVID-19 Antibody test

JERSEY, Channel Islands, Sept.  15, 2020  (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT) (the "Company"), a commercial-stage diagnostics company, today announced the closing of its previously announced underwritten public offering of 20,294,117 ordinary shares at a price to the public of $4.25 per share, which includes the exercise in full by the underwriters of their option to purchase up to 2,647,058 additional ordinary shares.  The net proceeds to the Company from this offering were approximately $80.5 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.

Quotient Limited Announces Closing of Underwritten Offering of Ordinary Shares

JERSEY, Channel Islands, Sept.  10, 2020  (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT) (the Company), a commercial-stage diagnostics company, today announced the upsize and pricing of a $75 million underwritten public offering.  The Company is offering 17,647,059 ordinary shares at a price to the public of $4.25 per share. The offering was upsized from the previously announced offering of $60 million.  The net proceeds to the Company from this offering are expected to be approximately $69.9 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. All of the ordinary shares sold in the offering were offered by the Company. In addition, the Company has granted the underwriters a 30 day option to purchase up to an additional 2,647,058 of its ordinary shares. The offering is expected to close on September 15, 2020, subject to customary closing conditions.

Quotient Limited Announces Upsize and Pricing of Underwritten Offering of Ordinary Shares

JERSEY, Channel Islands, Sept.  09, 2020  (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT) (the Company), a commercial-stage diagnostics company, today announced the Company intends to commence an underwritten public offering of $60 million of its ordinary shares. All of the ordinary shares to be sold in the offering will be offered by the Company. In addition, the Company intends to grant the underwriters a 30‑day option to purchase up to an additional 15% of the ordinary shares sold in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Quotient Limited Announces Proposed Underwritten Offering of Ordinary Shares

JERSEY, Channel Islands, Sept.  08, 2020  (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), headquartered in Eysins, Switzerland, today announced that the Company and Ortho Clinical Diagnostics (Ortho) have signed a binding letter of intent that confirms the termination of their former distribution agreement and related contracts and resolves all their disputes over the former distribution agreement. In addition, this ends the pending arbitration between the two companies and establishes a new distributor relationship focused solely on patient transfusion diagnostics.

Quotient Limited and Ortho Clinical Diagnostics Settle Arbitration and Sign Binding Letter of Intent Covering Patient Transfusion Diagnostics

JERSEY, Channel Islands, Aug.  27, 2020  (GLOBE NEWSWIRE) -- Bloodworks Northwest is now offering all blood donors across the Pacific Northwest free COVID-19 antibody testing with the possibility of discovering more qualified COVID-19 Convalescent Plasma (CCP) Donors. The testing is done with Quotient’s highly sensitive and specific COVID-19 antibody test utilizing Quotient’s high-throughput MosaiQ™ blood testing platform. The platform can process up to 3,000 samples a day, detecting antibodies with 100% sensitivity and 99.8% specificity.

Bloodworks Northwest Now Tests All Donors for COVID-19 Antibodies Looking for More Qualified Convalescent Plasma Donors

JERSEY, Channel Islands, Aug.  04, 2020  (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today published the latest investor presentation associated with the earnings call for fiscal quarter ended June 30, 2020.

Quotient Limited to Publish Quarterly Investor Presentation

Quotient Limited (QTNT) CEO Franz Walt on Q1 2021 Results - Earnings Call Transcript

Shares of Quotient (NASDAQ:QTNT) remained unaffected after the company reported Q1 results.

Quotient: Q1 Earnings Insights

Quotient (QTNT) delivered earnings and revenue surprises of 3.03% and 4.99%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Quotient (QTNT) Reports Q1 Loss, Tops Revenue Estimates

JERSEY, Channel Islands, Aug.  03, 2020  (GLOBE NEWSWIRE) --  Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today reported its first quarter fiscal 2021 results and summarized recent key developments.

Quotient Limited Reports First Quarter Fiscal 2021 Results and Business Update

JERSEY, Channel Islands, July  23, 2020  (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland today announced that Dr. Isabelle Buckle, Ph.D. and Dr. Catherine Larue, Ph.D. will join the Company’s Board of Directors, effective September 1, 2020.

Quotient Announces Equity Awards

JERSEY, Channel Islands, July  23, 2020  (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced changes in the composition of its board of directors that will take effect later this year.  Two of the Company's directors will be leaving the board and, effective September 1, 2020, two new directors will be joining.

Quotient Announces Appointment of Two New Board Members

JERSEY, Channel Islands, July  20, 2020  (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today reported that an independent study conducted in Madrid, Spain has confirmed the high performance characteristics of the Company's MosaiQ COVID-19 Antibody Microarray. The independent study found the MosaiQ COVID-19 Antibody Microarray demonstrated 100% sensitivity (ability to detect COVID-19 antibodies) and 99.8% specificity (ability to rule out the presence of COVID-19 antibodies).  These findings show the same sensitivity and specificity found in the Company's own earlier tests.

Quotient Limited Reports Impressive Results from an Independent SARS-CoV-2 Antibody Detection Study Conducted in Spain

JERSEY, Channel Islands, July  17, 2020  (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ended June 30, 2020 will be released before market open on Monday, August 3, 2020.

Quotient Limited to Report First Quarter 2021 Financial Results and Host Conference Call

Quotient Limited (QTNT) CEO Franz Walt on Q4 2020 Results - Earnings Call Transcript

Shares of Quotient (NASDAQ:QTNT) were unchanged in pre-market trading after the company reported Q4 results.

Quotient: Q4 Earnings Insights

JERSEY, Channel Islands, June  09, 2020  (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today summarized recent key achievements. These included Quotient's rapid development of a high performance COVID-19 antibody test based on its innovative MosaiQ™ platform and several commercial MosaiQ contracts. Quotient's European Field Trials in transfusion diagnostics recently restarted for the Company's expanded MosaiQ IH microarray. A CE Mark was obtained for the Company's initial SDS microarray. The Company also announced strong top line growth for both its fourth quarter ended March 31, 2020 and for the full financial year.

News for Quotient Stock (QTNT)